We use cookies to improve your experience. By your continued use of this site you accept such use.
Medicines for Malaria Venture

  • Multimedia content

  • Videos (1)
    • A child, Reagan gets to a healthcare facility to be treated for severe malaria with injectable artesenuate. But what if his family didn't manage to get him to a healthcare facility
  • Images (2)
    • Child suffering from severe malaria, Zambia. Image Credit Damien Schumann (1)
    • Child suffering from severe malaria, Zambia. Image Credit Damien Schumann (2)
  • Documents (4)
    • Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings
    • Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings
    • Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings
    • Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings
  • Audio (1)
  • All (8)
Source: Medicines for Malaria Venture |

Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings

Study will generate evidence on intervention used to buy time to reach a health facility

The new SEMA ReACT (SEvere MAlaria treatment with Rectal artesunate and Artemisinin-based Combination Therapy [in remote settings]) consortium aims to fill the evidence gap in the use of an intervention used to buy time to seek further care in remote contexts where health facility transfer is not feasible. Download document…

Medicines for Malaria Venture

  • Multimedia content

  • Images (1)
    • Pierre Hugo, MMV’s Senior Director of Market Dynamics and Global Partnerships and Dr. Nicaise Ndembi, Africa CDC’s Senior Science Advisor
  • All (1)
Source: Medicines for Malaria Venture |

Medicines for Malaria Venture and the Africa Centres for Disease Control and Prevention (CDC) sign Memorandum of Understanding to support African manufacturers

MMV and Africa CDC share a common goal of delivering quality-assured essential medicines produced in Africa

Medicines for Malaria Venture (MMV) (www.MMV.org) and the Africa Centres for Disease Control and Prevention (Africa CDC), have signed a Memorandum of Understanding (MoU), focused on strengthening African manufacturing of malaria medicines on the margins of the 2nd International Conference on Public Health in Africa (CPHIA 2022), taking place in Kigali,…

Medicines for Malaria Venture
Source: Medicines for Malaria Venture |

Strong Recommendation for Pyronaridine-Artesunate in Revised World Health Organization (WHO) Malaria Treatment Guidelines

Inclusion in the latest version of the WHO Guidelines for malaria is a key step towards broader use of the medicine

MMV (http://www.MMV.org) and Shin Poong Pharm. Co., Ltd. welcome the formal inclusion of Pyramax® (pyronaridine-artesunate) in the World Health Organization’s (WHO) Guidelines for Malaria (http://bit.ly/3EZSJep) following an extensive review process. The WHO’s Guidelines for the Treatment of Malaria are the standard reference which guide country-level policies for managing malaria. New…

Medicines for Malaria Venture
Source: Medicines for Malaria Venture |

First African-Manufactured Medicine to Prevent Malaria in Pregnant Women and Infants Quality-Approved by World Health Organization (WHO)

Universal Corporation Ltd (UCL), with support from MMV and Unitaid, becomes the first African manufacturer to gain WHO prequalification of sulfadoxine-pyrimethamine

Sulfadoxine/pyrimethamine (SP) is a well-tolerated, effective and affordable medicine used to prevent malaria in pregnant women and infants; Nearly all malaria cases and deaths occur in Africa, yet until now, the continent was completely reliant on imported quality-assured SP; This breakthrough responds to the need for local production of quality…